AffyImmune Therapeutics Expands Board of Directors with Key Appointments
Slice of Healthcare Team
Sep 24, 2024
Key Highlights
- AffyImmune Therapeutics announces the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to its Board of Directors.
- Appointments bolster AffyImmune’s AIC100 CAR T cell therapy development for advanced thyroid cancers and non-small cell lung cancer (NSCLC).
- Rutter and Nieva bring decades of experience in CMC regulatory strategy and clinical oncology.
- AffyImmune’s AIC100 is nearing completion of Phase 1 trials for thyroid cancer and moving toward Phase 2 for NSCLC.
Source: Business Wire
Notable Quotes
“ I am delighted to join AffyImmune’s Board and to work with the management team to bring industry-best CMC and supply chain practices, and ready AIC100 for registrational trials and commercial launch. ”
Rick Rutter, Ph.D., Former Executive Vice President, Biotherapeutics Pharmaceutical Sciences at Pfizer; Expert Consultant
“ Joining AffyImmune’s Board of Directors is an exciting opportunity to contribute to the expansion of AIC100 beyond advanced thyroid cancers, into larger indications such as NSCLC. ”
Jorge Nieva, M.D., Associate Professor of Clinical Medicine at Keck School of Medicine, University of Southern California
Heading
Hims & Hers Launches $99 GLP-1 Subscriptions for U.S. Service Heroes News Product News Read More Chris-Anne Roque Matthias Evers, Ph.D., Joins IMIDomics’ Board of Directors Hiring News News Read More Chris-Anne Roque CorriXR Therapeutics Appoints Jill Castilla to Board of Directors Hiring News News Read More Chris-Anne Roque Komodo Health Launches AI-Powered Tools: MapAI™ and MapExplorer™ News Product News Read More Chris-Anne Roque Aura Launches At-Home Health Check in New York, Offering Unmatched Convenience News Product News Read More Chris-Anne Roque August Health Introduces Billing & Payments Solution for Senior Living Operators News Product News Read More Chris-Anne Roque
-2e14ed90-63f5-4ce1-84fc-3fa9506b84be.png&w=3840&q=75)
